Weight gain after stopping Eli Lilly's new obesity treatment should help, not hurt the stock
Some Eli Lilly investors appear concerned about clinical trial data that showed patients regained weight after they stopped taking the company's obesity drug Zepbound. The situation seems rather clear-cut to us: It's no reason to sell. Eli…